This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Comparison of Prilosec Over-the-counter (OTC)® Versus Prevacid® for Gastric Acid Suppression

This study has been completed.
Information provided by:
Procter and Gamble Identifier:
First received: May 14, 2009
Last updated: December 22, 2010
Last verified: December 2010
The objective of this study is to compare Prilosec OTC® to Prevacid® for gastric acid suppression.

Condition Intervention Phase
Healthy Drug: Prilosec OTC (omeprazole-magnesium) Drug: Prevacid Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Basic Science
Official Title: Comparison of Prilosec OTC® Versus Prevacid ® for Gastric Acid Suppression

Resource links provided by NLM:

Further study details as provided by Procter and Gamble:

Primary Outcome Measures:
  • Mean Percent Time That Gastric pH > 4.0 on Day 5 [ Time Frame: 24 hours ]
    for 24 hours starting Day 5 for each period

Enrollment: 40
Study Start Date: April 2009
Study Completion Date: June 2009
Primary Completion Date: June 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: A
Prilosec OTC
Drug: Prilosec OTC (omeprazole-magnesium)
Prilosec OTC (omeprazole-magnesium 20.6 mg) tablet to be taken with a glass of water prior to breakfast
Active Comparator: B
Drug: Prevacid
Prevacid (15 mg lansoprazole) capsule to be taken with a glass of water prior to breakfast


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • normal subjects who are age 18-65
  • generally healthy
  • non-childbearing potential females or those using birth control

Exclusion Criteria:

  • history of significant GI disease
  • any significant medical illness
  • history of hypersensitivity, allergy or intolerance to omeprazole, lansoprazole or other proton pump inhibitors
  • currently using GI medications
  • GI disorder or surgery leading to impaired drug absorption
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00903448

United States, Oklahoma
Research Site
Oklahoma City, Oklahoma, United States, 73104
Sponsors and Collaborators
Procter and Gamble
Study Director: Simon H Magowan, MD Procter and Gamble
  More Information

Responsible Party: Simon H. Magowan, MD, Procter and Gamble Identifier: NCT00903448     History of Changes
Other Study ID Numbers: 2009010
Study First Received: May 14, 2009
Results First Received: August 4, 2010
Last Updated: December 22, 2010

Keywords provided by Procter and Gamble:
Normal Healthy Subject Population

Additional relevant MeSH terms:
Anti-Ulcer Agents
Gastrointestinal Agents
Proton Pump Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action processed this record on August 22, 2017